These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1334 related items for PubMed ID: 24678939
21. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, Pocock S, Tsioufis K, Konstantinidis D, Choi J, East C, Lauder L, Cohen DL, Kobayashi T, Schmid A, Lee DP, Ma A, Weil J, Agdirlioglu T, Schlaich MP, Shetty S, Devireddy CM, Lea J, Aoki J, Sharp ASP, Anderson R, Fahy M, DeBruin V, Brar S, Böhm M, SPYRAL HTN-ON MED Investigators. J Am Coll Cardiol; 2023 Nov 07; 82(19):1809-1823. PubMed ID: 37914510 [Abstract] [Full Text] [Related]
24. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P, Lobo MD, Fisher NDL, Daemen J, Bloch MJ, Basile J, Sanghvi K, Saxena M, Gosse P, Jenkins JS, Levy T, Persu A, Kably B, Claude L, Reeve-Stoffer H, McClure C, Kirtane AJ, RADIANCE-HTN Investigators. JAMA Cardiol; 2022 Dec 01; 7(12):1244-1252. PubMed ID: 36350593 [Abstract] [Full Text] [Related]
25. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, Urata H, Cho JM, Kim CJ, Choi SH, Shinohara K, Mukai Y, Ikemoto T, Nakamura M, Seki S, Matoba S, Shibata Y, Sugawara S, Yumoto K, Tamura K, Yoshihara F, Nakamura S, Kang WC, Shibasaki T, Dote K, Yokoi H, Matsuo A, Fujita H, Takahashi T, Kang HJ, Sakata Y, Horie K, Inoue N, Sasaki KI, Ueno T, Tomita H, Morino Y, Nojima Y, Kim CJ, Matsumoto T, Kai H, Nanto S. Hypertens Res; 2022 Feb 01; 45(2):221-231. PubMed ID: 34654905 [Abstract] [Full Text] [Related]
26. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ, Basile J, Wang Y, Saxena M, Lurz P, Rader F, Sayer J, Fisher NDL, Fouassier D, Barman NC, Reeve-Stoffer H, McClure C, Kirtane AJ, RADIANCE-HTN Investigators. Circulation; 2019 May 28; 139(22):2542-2553. PubMed ID: 30880441 [Abstract] [Full Text] [Related]
27. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Rosa J, Widimský P, Toušek P, Petrák O, Čurila K, Waldauf P, Bednář F, Zelinka T, Holaj R, Štrauch B, Šomlóová Z, Táborský M, Václavík J, Kociánová E, Branny M, Nykl I, Jiravský O, Widimský J. Hypertension; 2015 Feb 28; 65(2):407-13. PubMed ID: 25421981 [Abstract] [Full Text] [Related]
28. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Hypertension; 2014 Sep 28; 64(3):565-72. PubMed ID: 24935940 [Abstract] [Full Text] [Related]
29. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Clin Cardiol; 2012 Sep 28; 35(9):528-35. PubMed ID: 22573363 [Abstract] [Full Text] [Related]
30. Renal denervation therapy for the treatment of resistant hypertension: a position statement by the Canadian Hypertension Education Program. Khan NA, Herman RJ, Quinn RR, Rabkin SW, Ravani P, Tobe SW, Feldman RD, Wijeysundera HC, Padwal RS, Canadian Hypertension Education Program. Can J Cardiol; 2014 Jan 28; 30(1):16-21. PubMed ID: 24269056 [Abstract] [Full Text] [Related]
31. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, Pokushalov EA, Romanov AB. JAMA; 2020 Jan 21; 323(3):248-255. PubMed ID: 31961420 [Abstract] [Full Text] [Related]
32. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Hypertension; 2015 Dec 21; 66(6):1130-7. PubMed ID: 26558819 [Abstract] [Full Text] [Related]
33. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M, Lurz P, Sayer J, Bloch MJ, Basile J, Weber MA, Rump LC, Levy T, Sapoval M, Sanghvi K, Rader F, Fisher NDL, Gosse P, Abraham J, Claude L, Barman NC, McClure CK, Liu Y, Kirtane AJ, RADIANCE-HTN Investigators. JACC Cardiovasc Interv; 2020 Dec 28; 13(24):2922-2933. PubMed ID: 33357531 [Abstract] [Full Text] [Related]
34. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Eur Heart J; 2014 Jul 28; 35(26):1752-9. PubMed ID: 24898552 [Abstract] [Full Text] [Related]
35. Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension. Hering D, Nikoleishvili D, Imedadze A, Dughashvili G, Klimiashvili Z, Bekaia E, Shengelia T, Kobalava M, Goguadze O, Emukhvari T, Druker V, Sackner-Bernstein J, Weber MA. Hypertension; 2022 Dec 28; 79(12):2787-2795. PubMed ID: 36254733 [Abstract] [Full Text] [Related]
36. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Lancet; 2014 Feb 15; 383(9917):622-9. PubMed ID: 24210779 [Abstract] [Full Text] [Related]
37. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Böhm M, Lengelé JP, Wojakowski W, Schmieder R, van der Giet M, Parise H, Haratani N, Pathak A, Persu A. JACC Cardiovasc Interv; 2020 Feb 24; 13(4):471-484. PubMed ID: 32081241 [Abstract] [Full Text] [Related]
38. Efficacy and safety of renal denervation in elderly patients with resistant hypertension. Ziegler AK, Bertog S, Kaltenbach B, Id D, Franke J, Hofmann I, Vaskelyte L, Sievert H. Catheter Cardiovasc Interv; 2015 Aug 24; 86(2):299-303. PubMed ID: 23983010 [Abstract] [Full Text] [Related]
39. Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial. Jiang X, Mahfoud F, Li W, Dong H, Yu J, Yu S, Chen X, Wang P, Li Z, Lauder L, Wang Z, Ji Z, Dong Y, Han B, Zhu Z, Chen Y, Xu J, Zhao X, Fan W, Xie W, Hubbard B, Hu X, Kario K, Gao R. Circulation; 2024 Nov 12; 150(20):1588-1598. PubMed ID: 39229700 [Abstract] [Full Text] [Related]
40. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Böhm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder RE, Townsend RR, Kulenthiran S, Ukena C, Pocock S, Ewen S, Weil J, Fahy M, Mahfoud F. J Am Coll Cardiol; 2021 Sep 07; 78(10):1028-1038. PubMed ID: 34474735 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]